Sands Capital Life Sciences Pulse Fund II, L.P.

Insider Reports History

Location
Arlington, VA
Signature
Sands Capital Life Sciences Pulse Fund II, L.P., By: Sands Capital Life Sciences Pulse Fund II-GP, L.P., its General Partner, By: Sands Capital Life Sciences Pulse Fund II-GP, LLC, its General Partner, By: /s/ Jonathan Goodman, General Counsel
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Sands Capital Life Sciences Pulse Fund II, L.P.:

Company Role Class Num Shares Value Price $ Report Date Ownership
Inhibikase Therapeutics, Inc. 10%+ Owner Common Stock 13,018,965 $18,877,499 $1.45 21 Nov 2025 Direct

Insider Reports Filed by Sands Capital Life Sciences Pulse Fund II, L.P.

Symbol Company Period Transactions Value $ Form Type Role Filing Time
IKT Inhibikase Therapeutics, Inc. 21 Nov 2025 1 +$2,999,999 4 10%+ Owner 24 Nov 2025, 15:47
IKT Inhibikase Therapeutics, Inc. 06 Jun 2025 0 $0 3/A 10%+ Owner 15 Jul 2025, 11:15
IKT Inhibikase Therapeutics, Inc. 21 Oct 2024 0 $0 3 10%+ Owner 25 Oct 2024, 17:52